Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,153 GBX | +0.35% | +0.96% | +9.39% |
May. 08 | UBS raises Centrica to 'buy' from 'neutral | AN |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its low valuation, with P/E ratio at 8.46 and 7.76 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Property & Casualty Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.39% | 5.01B | C+ | ||
+54.21% | 68.15B | B- | ||
+12.21% | 50.45B | C+ | ||
+11.79% | 48.76B | B | ||
+17.92% | 43.56B | B- | ||
+35.41% | 37.61B | B- | ||
+69.69% | 31.77B | B | ||
+12.11% | 29.63B | B- | ||
+27.75% | 25.69B | C- | ||
+1.99% | 21.91B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HSX Stock
- Ratings Hiscox Ltd